Navigation Links
VCU receives NIH grant to examine the biology of allergic disease
Date:7/17/2013

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

The five-year grant will be led by John Ryan, Ph.D., associate professor in the Department of Biology in the VCU College of Humanities and Sciences. Ryan and his colleagues will investigate how interleukin-10, IL-10, controls mast cell homeostasis.

IL-10 is a type of signaling protein known for its anti-inflammatory effects. Mast cells, which are known to play a central role in asthma and allergy, are packed with granules containing histamine and are found in nearly all tissues, with the exception of blood. Inflammatory substances such as histamine, heparin and a number of cytokines are rapidly released into tissues and blood when a mast cell is activated. This results in an allergic response.

"This project is helping us understand how mast cells, the causative agent of allergic disease and asthma, are naturally regulated," said Ryan.

"Our data suggest that factors produced by other white blood cells, especially the cytokine IL-10, function as feedback regulators to prevent mast cell-mediated inflammation from becoming chronic. We have recently found that genetic background can alter responsiveness to this feedback regulation, which could predispose individuals to chronic allergic diseases like asthma."

Earlier this year, Ryan received a $1.8 million NIH National Institute of Allergy and Infectious Diseases grant for another project investigating the molecular interaction of two enzymes and their involvement in inflammation. This project is designed to understand how the production of autoantibodies leads to arthritis.

"We are specifically interested in how two enzymes,
'/>"/>

Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-828-1231
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Carnegies Chris Field receives Max Planck Research Prize
2. Penn receives prestigious national award for breakthrough in gene therapy
3. Peihua Jiang receives Ajinomoto Award for Young Investigators in Gustation from AChemS
4. Forsyth Institute receives $4.1 million grant for new center
5. Einstein receives $12 million grant to develop device for preventing HIV infection
6. Wayne State vision restoration technology receives Notice of Allowance for US patent app
7. BU researcher receives highest honor from the National Birth Defects Prevention Network
8. Geneticist Svante Pääbo receives the $500,000 Gruber Genetics Prize
9. Artificial retina receives FDA approval
10. NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists
11. Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... levels of folate in their red blood cells were more ... a chemical off switch for genes, researchers report in the ... co-author Jean-Pierre Issa, M.D., professor in MD Anderson,s Department of ... of aging, such as heart disease. Methyl groups attach to ...
... 2010)A class of drugs thought to kill cancer cells may ... normal immune cells, resulting in reduced cancer growth and spreada ... evaluated in the future. Researchers at the University of ... fifth most common cancer in the United States. Bladder cancer ...
... release of an online tool that will help scientists ... a cell,s transcription machinery where to start reading in ... Promoter Database (MPromDb) integrates the genome sequencing data generated ... mouse genomics. MPromDb pinpoints known promoters and predicts where ...
Cached Biology News:High red blood cell folate levels linked to silenced tumor-suppressors 2High red blood cell folate levels linked to silenced tumor-suppressors 3Some cancer drugs may block cellular 'cross talk' but not kill cancer cells 2New annotated database sifts through mountains of sequencing data to find gene promoters 2New annotated database sifts through mountains of sequencing data to find gene promoters 3
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... May 25, 2011 /PRNewswire/ -- Vermillion, ... today announced that the United States Patent and Trademark Office ... entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s Disease." ... as well as combinations that include these biomarkers. ...
... 2011 VIVUS, Inc. (NASDAQ: ... 3, placebo-controlled clinical trial of the investigational drug avanafil ... following a radical prostatectomy. The study (REVIVE-RP, TA-303) met ... erectile function as measured by the Sexual Encounter Profile ...
... 24, 2011 Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – today announced ... rule 5550(a)(2), which concerns minimum bid price listing ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 2VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 4VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 5Spherix Regains Compliance With NASDAQ Listing Rule 2
...
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... Evrogen TRIMMER-DIRECT kit is developed for ... sequences and intended for directional cloning. ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: